Background: Three main phenotypes describe heart failure (HF) according to left ventricular ejection fraction (LVEF). This study aims to describe the characteristics, management and outcomes of hospitalised patients with HF categorised by LVEF. Methods: The Malaysian National Heart Failure (MY-HF) Registry is a 3-year prospective, observational study of patients admitted for acute HF. This analysis includes 2,651 patients categorised into: HF with reduced ejection fraction (HFrEF; LVEF ≤40%), HF with mildly reduced ejection fraction (HFmrEF; LVEF 41−49%) and HF with preserved ejection fraction (HFpEF; LVEF ≥50%). Hospital readmission and mortality outcomes at 30 days and 1 year were examined. Results: The HFrEF subgroup represented the largest proportion of patients (66.2%), followed by HFpEF (22.1%) and HFmrEF (11.7%). The HFpEF subgroup was older (mean age 65.3 ± 13.3 years), had the highest proportion of females (53.5%) and had more patients with de novo HF at admission than the HFrEF subgroup (41.9% versus 31.4%). Comorbidities, such as hypertension, AF and chronic kidney disease, were more prevalent in the HFpEF than HFrEF subgroup. Conversely, more HFrEF patients had ischaemic heart disease and elevated N-terminal pro B-type natriuretic peptide levels (≥1,000 pg/ml). Similar 30-day and 1-year outcome rates were observed across the subgroups except for lower 30-day hospital readmission (p=0.024) and 1-year mortality (p=0.005) in the HFpEF subgroup. Older age (>60 years) and New York Heart Association class III–IV increased 1-year readmission risk. Conclusion: The MY-HF Registry highlighted high 1-year mortality in patients with HF, especially those with advanced NYHA class or chronic kidney disease. This suggests potential areas for improvement in HF management, including medication regimens, adherence and comorbidity management. Future research exploring these factors could significantly impact clinical practice and patient outcomes.
24 March 2026 in Journal of Asian Pacific Society of Cardiology
Background: Heart failure (HF) is a leading cause of morbidity and mortality globally, with Southeast Asia seeing a rising disease burden. Multidisciplinary HF clinics (MDHFCs) offer a structured approach to optimise guideline-directed medical therapy, yet their effectiveness in middle-income countries remains underreported. Methods: This retrospective observational study aims to evaluate clinical outcomes and treatment optimisation in patients with HF with reduced ejection fraction enrolled in a MDHFC in Sarawak, Malaysia. The study included 172 patients enrolled from 2016 to 2020 at Sarawak Heart Centre. Patients were followed for 12 months. Primary outcome was a composite of cardiovascular mortality, HF hospitalisation or ambulatory worsening HF visits. Secondary outcomes included changes in New York Heart Association class, echocardiographic parameters and prescriptions for HF therapies. Results: Over 12 months, no cardiovascular deaths were recorded. HF hospitalisation and ambulatory worsening HF occurred in 9.5% and 11.3% of patients, respectively. Significant improvements in left ventricular ejection fraction (24.5–39.1%, p<0.001) and New York Heart Association class were observed. Uptake of angiotensin receptor blockers, angiotensin receptor–neprilysin inhibitor, β-blockers, mineralocorticoid receptor antagonists and sodium–glucose cotransporter-2 inhibitors increased markedly, with β-blockers prescribed in 91.5% of patients. Triple therapy use rose from 49.4% to 59.1%; quadruple therapy uptake remained low (1.8%). Conclusion: The MDHFC model improved clinical outcomes, functional status and medication optimisation despite resource limitations. These findings support the feasibility and effectiveness of MDHFCs in similar healthcare settings and highlight their potential scalability in middle-income countries.
26 April 2022 in Journal of Asian Pacific Society of Cardiology
Background: N-terminal pro-brain natriuretic peptide (NT-proBNP) provides prognostic information regarding the risk of death, acute heart failure and the development of AF in patients with acute coronary syndrome. While there are established cut-off values for the association between clinical risk assessment scores and in-hospital mortality, there is no clear cut-off value for NT-proBNP to guide risk stratification in patients with acute MI (AMI). Our study sought to evaluate the cut-off values of NT-proBNP in all-cause mortality post AMI and to compare with other available risk assessment scores. Methods: We conducted a multi-centre, prospective, observational study involving 411 patients admitted for AMI. Plasma NT-proBNP was assessed within 24 hours of admission. Results: One-year all-cause mortality occurred in 31 (7.6%) of 411 patients. NT-proBNP ≥404 pg/ml had an area under the curve of 0.66 (95% CI [0.54–0.77]; p=0.004) to predict all-cause mortality at 1 year (sensitivity: 80.6%; specificity: 36.9%; positive predictive value: 9.47%; negative predictive value: 95.89%). Using the Youden index, an NT-proBNP level ≥1,995 pg/ml was an independent predictor of all-cause mortality at 1 year (adjusted HR 2.6; 95% CI [1.3–5.5]; p=0.010), regardless of cardiovascular disease risk factors or revascularisation status. There were no significant differences among the predictive values of NT-proBNP, Thrombolysis in MI risk score, Global Registry of Acute Coronary Events risk score and left ventricular ejection fraction in predicting all-cause mortality at 1 year (p>0.05). Conclusion: NT-proBNP level ≥1,995 pg/ml measured within 24 hours of admission for AMI was associated with higher all-cause mortality at 1 year. Randomised controlled trials are needed to further validate the usefulness of NT-proBNP for risk stratification in patients with AMI.
1 December 2019 in International Journal of Cardiology